Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PRKCA | P17252 | 2/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11365522 | 0.87 | HPGD (0.40) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL813771 | 0.87 | CYP1A2 (0.50) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL1169267 | 0.83 | CYP1A2 (0.42) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL9246055 | 0.83 | CYP1A2 (0.42) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL11992984 | 0.81 | LMNA (0.45) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL12819487 | 0.81 | LMNA (0.45) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL4476581 | 0.81 | LMNA (0.45) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL148756 | 0.79 | TRPA1 (0.48) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL7782492 | 0.79 | HPGD (0.41) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL7782494 | 0.79 | HPGD (0.41) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11680070-B2 | Thieno[2,3-c]pyridazin-4(1H)-one derivative and application thereof | MEDSHINE DISCOVERY INC. (CN) | 2023-06-20 | — | — | US | disclosed |
| EP-3388425-B1 | AMINOAZOLE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2020-08-05 | — | — | EP | disclosed |
| WO-2017099237-A1 | AMINOAZOLE DERIVATIVE | 帝人ファーマ株式会社 | 2017-06-15 | — | — | WO | disclosed |
| EP-2668177-B1 | SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-8772305-B2 | Substituted pyridinyl-pyrimidines and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| EP-2668177-A1 | SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2013-12-04 | — | — | EP | disclosed |
| US-20130023502-A1 | SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| WO-2012101013-A1 | SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | WO | disclosed |
| US-5874097-A | ANALYZING AIR SAMPLES NEAR OR IN BUILDINGS FOR THE PRESENCE OF A REPORTER MOLECULE, PREFERABLY NAPHTHALENE, TO INDICATE THE PRESENCE OF A TERMITE NEST | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 1999-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023502-A1 | SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | ADORA1, P2RY1, P2RY11 | CYP1A2 104/4885CYP2D6 26/4885PKM 1576/4885 |
| US-11680070-B2 | Thieno[2,3-c]pyridazin-4(1H)-one derivative and application thereof | ACACB, ACACA, NAT1 | CYP1A2 92/4885CYP2D6 941/4885PKM 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.